1.
Proc (Bayl Univ Med Cent)
; 36(1): 83-84, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36578622
RESUMO
We report a case of recurrent pericarditis as an immune-related adverse event in a 47-year-old man with de novo metastatic renal cell carcinoma. After first-line treatment with sunitinib failed, he received three cycles of nivolumab and developed pericarditis following each cycle. The third cycle was accompanied by colchicine as a secondary prophylaxis. Pericarditis is an uncommon and potentially life-threatening immune-related adverse event, if not managed promptly.